Purpose

Treatments are needed to improve outcomes among patients hospitalized for COVID-19, including direct-acting antiviral (DAA) agents to mitigate the pathology driven by ongoing viral replication. This trial will evaluate S-217622 (ensitrelvir), an anti-SARS-CoV2 3C-like protease inhibitor (PI) developed by Shionogi &; Co. Ltd. The study design is a randomized, placebo-controlled, multi-center international clinical trial that will evaluate the clinical efficacy of ensitrelvir when given in addition to standard of care (SOC) for inpatients with COVID-19. The SOC will be determined by local established guidelines and may include additional DAA (e.g., remdesivir) and immunomodulatory treatment strategies. Certain SOC treatments will be pre-specified prior to randomization.

Condition

Eligibility

Eligible Ages
Over 18 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Age ≥18 years. - Informed consent for trial participation. - Hospital admission (or boarding in an emergency department or other area awaiting hospital admission) with signs and/or symptoms of a respiratory infection. - Confirmation of SARS-CoV2 infection by nucleic acid test (NAT) or equivalent non- NAT test [list of approved tests is in the PIM] collected within the prior 14 days. - Onset of symptoms attributable to SARS-CoV2 infection occurred within 14 days before randomization. - Hospitalized for the management of COVID-19, with signs and/or symptoms suggestive of lower respiratory tract infection.

Exclusion Criteria

  • The patient is expected to be discharged from the hospital within the next 24 hours. - Medical condition other than the acute respiratory infection (and its manifestations) that is likely to result in death within 7 days of randomization. - Use of a strong CYP3A inducer within 14 days prior to enrollment - Moribund condition, defined as prior cardiac arrest during this hospitalization and life expectancy less than 48 hours of randomization. - Patient undergoing comfort care measures only such that treatment focuses on end-of- life symptom management over prolongation of life. - Expected inability or unwillingness to participate in study procedures. - In the opinion of the investigator, participation in a trial is not in the best interest of the patient. - Allergy to investigational agent or vehicle - Use of a concomitant medication that is contraindicated due to a drug-drug interaction with S-217622 - Moderate to severe hepatic impairment (i.e., Child-Pugh class B or C) or acute liver failure. - Known estimated glomerular filtration rate (eGRF) <30 mL/min/1.73m 2 - Continuous renal replacement therapy or chronic dialysis - Current pregnancy - Current breastfeeding and unwillingness to defer breastfeeding for 30 days after the last dose of investigational agent. - Women of child-bearing potential who are unwilling to abstain from sexual intercourse with men or practice appropriate contraception through 30 days from the last dose of the investigational agent. - Men who are unwilling to abstain from sexual intercourse with women of child- bearing potential or to use barrier contraception through 30 days from the last dose of the investigational agent. - Inability to take investigational agent in tablet form by mouth.

Study Design

Phase
Phase 3
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
Double (Participant, Investigator)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
S-217622 (ensitrelvir) plus standard of care (SOC)
Study investigational agent (ensitrelvir) will be administered as oral tablets with dosing of 375mg (3 tabs) once on Day 0 and 125mg (1 tab) once daily on Days 1-4. All participants will receive the full 5-day course, including those who are discharged from hospitalization prior to Day 4.
  • Drug: Shionogi Protease Inhibitor (S-217622)
    S-217622 (ensitrelvir) is an oral anti-SARS-CoV2 PI that does not require ritonavir co-administration The dose is 375/125 (375 mg on Day 0, followed by 125 mg daily on Days 1-4).
    Other names:
    • ensitrelvir
Placebo Comparator
placebo plus standard of care (SOC)
Study investigational placebo will be administered as oral tablets with dosing of 375mg (3 tabs) once on Day 0 and 125mg (1 tab) once daily on Days 1-4. All participants will receive the full 5-day course, including those who are discharged from hospitalization prior to Day 4.
  • Drug: placebo
    Placebo is an oral tablet administered once (3 tabs) on Day 0 and once (1 tab) daily on days 1-4, 5-day course.

Recruiting Locations

University of Alabama Birmingham University Hospital (Site 213-002)
Birmingham, Alabama 35233
Contact:
Nashville ICC
strivenash@insight-trials.org

Banner University Medical Center Tucson (Site 206-004)
Tucson, Arizona 85719
Contact:
Nashville ICC
strivenash@insight-trials.org

Southern Arizona VA Healthcare System (Site 074-009)
Tucson, Arizona 85723
Contact:
VA ICC
striveva@insight-trials.org

UCSF Fresno (Site 203-005)
Fresno, California 93721
Contact:
Nashville ICC
strivenash@insight-trials.org

VA Loma Linda Healthcare System (Site 074-017)
Loma Linda, California 92357
Contact:
VA ICC

MemorialCare Health System (Site 066-003
Long Beach, California 90806
Contact:
Washington ICC
strivewdc@insight-trials.org

VA Long Beach Healthcare System (Site 074-026)
Long Beach, California 90822
Contact:
VA ICC
striveva@insight-trials.org

Cedars-Sinai Medical Center (Site 208-002)
Los Angeles, California 90048
Contact:
Nashville ICC
strivenash@insight-trials.org

Ronald Reagan UCLA Medical Center (Site 203-002)
Los Angeles, California 90095
Contact:
Nashville ICC
strivenash@insight-trials.org

VA Northern California Health Care System (Site 074-023)
Mather, California 95655
Contact:
VA ICC
striveva@insight-trials.org

Hoag Memorial Hospital Presbyterian (Site 080-026)
Newport Beach, California 92663
Contact:
Hennepin ICC
strivehenn@insight-trials.org

Veterans Affairs Palo Alto Health Care System (VAPAHCS) (Site 074-005)
Palo Alto, California 94304
Contact:
VA ICC
striveva@insight-trials.org

UC Davis Health (Site 203-004)
Sacramento, California 95817
Contact:
Nashville ICC

VA San Diego Healthcare System (Site 074-016)
San Diego, California 92161
Contact:
VA ICC
striveva@insight-trials.org

Zuckerberg San Francisco General Hospital and Trauma Center (Site 213-007)
San Francisco, California 94110
Contact:
Nashville ICC
strivenash@insight-trials.org

UCSF Medical Center at Mount Zion (203-007)
San Francisco, California 94115
Contact:
Nashville ICC
strivenash@insight-trials.org

San Francisco VAMC (Site 074-002)
San Francisco, California 94121
Contact:
VA ICC
striveva@insight-trials.org

University of California San Francisco (Site 203-001)
San Francisco, California 94143
Contact:
Nashville ICC

Stanford University Hospital & Clinics (Site 203-003)
Stanford, California 94305
Contact:
Nashville ICC
strivenash@insight-trials.org

Lundquist Institute for Biomedical Innovation (Site 066-002)
Torrance, California 90502
Contact:
Washington ICC
strivewdc@insight-trials.org

Rocky Mountain Regional VA Medical Center (Site 074-010)
Aurora, Colorado 80045
Contact:
VA ICC
striveva@insight-trials.org

University of Colorado Hospital (Site 204-001)
Aurora, Colorado 80045
Contact:
Nashville ICC
strivenash@insight-trials.org

Public Health Institute at Denver Health (Site 017-004)
Denver, Colorado 80204
Contact:
Washington ICC
strivewdc@insight-trials.org

Yale University (Site 025-001)
New Haven, Connecticut 06510
Contact:
Washington ICC
strivewdc@insight-trials.org

MedStar Health Research Institute/MedStar Washington Hospital Center (Site 009-021)
Washington, District of Columbia 20010
Contact:
Washington ICC
strivewdc@insight-trials.org

Washington DC VA Medical Center (Site 009-004)
Washington, District of Columbia 20422
Contact:
Washington ICC
strivewdc@insight-trials.org

University of Florida - Gainesville (Site 201-004)
Gainesville, Florida 32610
Contact:
Washington ICC
strivewdc@insight-trials.org

Miami VA Healthcare System (Site 074-003)
Miami, Florida 33125
Contact:
VA ICC
striveva@insight-trials.org

Orlando VA Medical Center (Site 074-032)
Orlando, Florida 32827
Contact:
VA ICC
striveva@insight-trials.org

Tampa General Hospital (032-001)
Tampa, Florida 33606
Contact:
Washington ICC
strivewdc@insight-trials.org

University of Illinois at Chicago (Site 008-012)
Chicago, Illinois 60612
Contact:
Hennepin ICC
strivehenn@insight-trials.org

Carle Foundation Hospital (Site 080-049)
Urbana, Illinois 61801
Contact:
Hennepin ICC
strivehenn@insight-trials.org

Lutheran Medical Group (Site 301-010)
Fort Wayne, Indiana 46804
Contact:
New York ICC
striveny@insight-trials.org

The University of Kansas Hospital (Site 080-044)
Kansas City, Kansas 66160
Contact:
Hennepin ICC
strivehenn@insight-trials.org

University of Kentucky (Site 210-004)
Lexington, Kentucky 40536
Contact:
Nashville ICC
strivenash@insight-trials.org

NIH Clinical Center (Site 080-043)
Bethesda, Maryland 20892
Contact:
Hennepin ICC
strivehenn@insight-trials.org

Massachusetts General Hospital (202-002)
Boston, Massachusetts 02114
Contact:
Nashville ICC
strivenash@insight-trials.org

Beth Israel Deaconess Medical Center (Site 202-001)
Boston, Massachusetts 02215
Contact:
Nashville ICC
strivenash@insight-trials.org

Baystate Medical Center (Site 201-001)
Springfield, Massachusetts 01199
Contact:
Nashville ICC
strivenash@insight-trials.org

UMass Chan Medical School (Site 080-007)
Worcester, Massachusetts 01655
Contact:
Washington ICC

VA Ann Arbor Healthcare System (Site 074-028)
Ann Arbor, Michigan 48105
Contact:
VA ICC
striveva@insight-trials.org

Henry Ford Health System (Site 014-001)
Detroit, Michigan 48202
Contact:
Washington ICC

Sinai-Grace Hospital (Site 205-005)
Detroit, Michigan 48235
Contact:
Nashville ICC
strivenash@insight-trials.org

Hennepin Healthcare Research Institute (Site 027-001)
Minneapolis, Minnesota 55415
Contact:
Hennepin ICC

M Health Fairview University of Minnesota Medical Center (Site 112-001)
Minneapolis, Minnesota 55455
Contact:
Hennepin ICC
strivehenn@insight-trials.org

University of Minnesota
Minneapolis, Minnesota 55455
Contact:
Rebecca Schoenecker
sitereg@insight-trials.org

Mayo Clinic (Site 054-001)
Rochester, Minnesota 55905
Contact:
Hennepin ICC
strivehenn@insight-trials.org

University of Mississippi Medical Center (Site 202-005)
Jackson, Mississippi 39216
Contact:
Nashville ICC
strivenash@insight-trials.org

Washington University School of Medicine (Site 003-001)
Saint Louis, Missouri 63110
Contact:
Washington ICC

University of Nebraska Medical Center (Site 080-045)
Omaha, Nebraska 68198
Contact:
Hennepin ICC
strivehenn@insight-trials.org

Dartmouth-Hitchcock Medical Center (301-024)
Lebanon, New Hampshire 03756
Contact:
New York ICC
striveny@insight-trials.org

Cooper University Hospital (Site 019-001)
Camden, New Jersey 08103
Contact:
Washington ICC
strivewdc@insight-trials.org

Hackensack Meridian Health (Site 301-030)
Hackensack, New Jersey 07601
Contact:
New York ICC
striveny@insight-trials.org

New Jersey Medical School Clinical Research Center (028-001)
Newark, New Jersey 07103
Contact:
Washington ICC
strivewdc@insight-trials.org

University of New Mexico Hospital (Site 213-008)
Albuquerque, New Mexico 87106
Contact:
Nashville ICC
strivenash@insight-trials.org

CHRISTUS - St. Vincent (Site 080-051)
Santa Fe, New Mexico 87505
Contact:
Hennepin ICC
strivehenn@insight-trials.org

Lincoln Medical Center (Site 003-016)
Bronx, New York 10451
Contact:
Washington ICC
strivewdc@insight-trials.org

Montefiore Medical Center - Moses Hospital (Site 206-001)
Bronx, New York 10467
Contact:
Nashville ICC
strivenash@insight-trials.org

Montefiore Medical Center - Weiler campus (Site 206-003)
Bronx, New York 10467
Contact:
Nashville ICC
strivenash@insight-trials.org

James J. Peters VAMC (Site 023-003)
Bronx, New York 10468
Contact:
VA ICC
striveva@insight-trials.org

NYU Brooklyn (301-033)
Brooklyn, New York 11220
Contact:
New York ICC
striveny@insight-trials.org

Mount Sinai Queens (Site 081-105)
Long Island City, New York 11102
Contact:
New York ICC

NYU Long Island (301-034)
Mineola, New York 11501
Contact:
New York ICC
striveny@insight-trials.org

New York University Tisch Hospital (Site 301-013)
New York, New York 10016
Contact:
New York ICC
striveny@insight-trials.org

Mount Sinai Medical Center (Site 301-012)
New York, New York 10029
Contact:
New York ICC
striveny@insight-trials.org

NYC Health + Hospital Harlem (Site 003-003)
New York, New York 10037
Contact:
Washington ICC
strivewdc@insight-trials.org

Weill Cornell Clinical Research Unit (065-001)
New York, New York 10065
Contact:
Washington ICC
strivewdc@insight-trials.org

St. Lawrence Health System (Site 301-029)
Potsdam, New York 13676
Contact:
New York ICC
striveny@insight-trials.org

Duke University Hospital (Site 301-006)
Durham, North Carolina 27710
Contact:
New York ICC
striveny@insight-trials.org

Wake Forest Baptist Health (Site 210-001)
Winston-Salem, North Carolina 27157
Contact:
Nashville ICC
strivenash@insight-trials.org

University of Cincinnati Medical Center (Site 207-003)
Cincinnati, Ohio 45219
Contact:
Nashville ICC
strivenash@insight-trials.org

Cleveland Clinic Foundation (Site 207-001)
Cleveland, Ohio 44195
Contact:
Nashville ICC
strivenash@insight-trials.org

Ohio State University Wexner Medical Center (Site 207-004)
Columbus, Ohio 43210
Contact:
Nashville ICC
strivenash@insight-trials.org

Portland VA Health Care System (074-024)
Portland, Oregon 97239
Contact:
VA ICC
striveva@insight-trials.org

Penn State Health Milton S. Hershey Medical Center (Site 209-002)
Hershey, Pennsylvania 17033
Contact:
Hennepin ICC
strivehenn@insight-trials.org

Rhode Island Hospital (Site 080-036)
Providence, Rhode Island 02903
Contact:
Hennepin ICC
strivehenn@insight-trials.org

The Miriam Hospital (Site 080-039)
Providence, Rhode Island 02906
Contact:
Hennepin ICC
strivehenn@insight-trials.org

Kent County Memorial Hospital (080-048)
Warwick, Rhode Island 02886
Contact:
Hennepin ICC
strivehen@insight-trials.org

Ralph H. Johnson VA Medical Center (Site 074-015)
Charleston, South Carolina 29401
Contact:
VA ICC
striveva@insight-trials.org

Medical University of South Carolina (Site 210-002)
Charleston, South Carolina 29425
Contact:
Nashville ICC
strivenash@insight-trials.org

Monument Health Rapid City Hospital (Site 213-005)
Rapid City, South Dakota 57701
Contact:
Nashville ICC
strivenash@insight-trials.org

Vanderbilt University Medical Center (Site 212-001)
Nashville, Tennessee 37212
Contact:
Nashville ICC

Hendrick Medical Center (Site 080-014)
Abilene, Texas 79601
Contact:
Hennepin ICC

CHRISTUS Spohn Shoreline Hospital (Site 080-001)
Corpus Christi, Texas 78405
Contact:
Hennepin ICC
strivehenn@insight-trials.org

Baylor, Scott and White Health (301-003)
Dallas, Texas 75246
Contact:
New York ICC
striveny@insight-trials.org

Parkland Health and Hospital Systems (Site 084-002)
Dallas, Texas 75390
Contact:
Washington ICC
strivewdc@insight-trials.org

UT Southwestern Medical Center (Site 084-001)
Dallas, Texas 75390
Contact:
Washington ICC
strivewdc@insight-trials.org

Houston Methodist Hospital (Site 301-028)
Houston, Texas 77030
Contact:
Hennepin ICC
strivehenn@insight-trials.org

MEDVAMC (Site 074-006)
Houston, Texas 77030
Contact:
VA ICC
striveva@insight-trials.org

University of Texas Health Science Center (Site 203-006)
Houston, Texas 77030
Contact:
Nashville ICC
strivenash@insight-trials.org

CHRISTUS Good Shepherd Medical Center (Site 080-031)
Longview, Texas 75601
Contact:
Hennepin ICC
strivehenn@insight-trials.org

UT Health San Antonio (Site 009-022)
San Antonio, Texas 78229
Contact:
Washington ICC
strivewdc@insight-trials.org

Intermountain Medical Center (Site 211-001)
Murray, Utah 84107
Contact:
Nashville ICC
strivenash@insight-trials.org

University of Utah Health (Site 211-002)
Salt Lake City, Utah 84108
Contact:
Nashville ICC
strivenash@insight-trials.org

University of Virginia Health System, University Hospital (Site 210-003)
Charlottesville, Virginia 22908
Contact:
Nashville ICC
strivenash@insight-trials.org

Salem VA Medical Center (Site 074-014)
Salem, Virginia 24153
Contact:
VA ICC

Harborview Medical Center (208-001)
Seattle, Washington 98104
Contact:
Nashville ICC
strivenash@insight-trials.org

Providence (Sacred Heart) (Site 213-004)
Spokane, Washington 99204
Contact:
Nashville ICC
strivenash@insight-trials.org

West Virginia University Medicine
Morgantown, West Virginia 26506
Contact:
New York ICC
striveny@insight-trials.org

William S. Middleton Memorial Veterans Hospital (074-030)
Madison, Wisconsin 53705
Contact:
Veterans Affairs ICC
striveva@insight-trials.org

Froedtert Memorial Lutheran Hospital (052-001)
Milwaukee, Wisconsin 53226
Contact:
Washington ICC
strivewdc@insight-trials.org

VA Caribbean Health Care (074-033)
San Juan, Puerto Rico 00921-3201
Contact:
Veterans Affairs ICC
striveva@insight-trials.org

More Details

NCT ID
NCT05605093
Status
Recruiting
Sponsor
University of Minnesota

Study Contact

Cavan Reilly, PhD
612-624-9644
cavanr@biostat.umn.edu

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.